UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_____________________________________

SCHEDULE 14A

(RULE 14a-101)
SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(AMENDMENT NO.)

_____________________________________

Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒

Check the appropriate box:

☐	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐	Definitive Proxy Statement
☐	Definitive Additional Materials
☒	Soliciting Material Under Rule 14a-12

Zevra Therapeutics, Inc.
(Name of registrant as specified in its charter)

DANIEL J. MANGLESS
TRAVIS C. MICKLE, PhD
ARTHUR C. REGAN
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

-with copies to-

Peter D. Fetzer

Foley & Lardner LLP
777 East Wisconsin Avenue

Milwaukee, WI 53202-5306

(414) 297-5596

Payment of Filing Fee (Check all boxes that apply):

☒	No fee required
☐	Fee paid previously with preliminary materials
☐	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Proxy Communications

Daniel J. Mangless has filed a preliminary proxy statement and accompanying BLUE proxy card with the U.S. Securities and Exchange Commission, to be used to solicit votes for the election of Travis C. Mickle, PhD and Arthur C. Regan to the Board of Directors of Zevra Therapeutics, Inc., a Delaware corporation (the “Company”), at the Company’s 2025 Annual Meeting of Stockholders scheduled for May 29, 2025.

Attached hereto are screenshots of posts on Stocktwits, a social media site, that Mr. Regan made between April 1, 2025 and April 10, 2025.

Important Information

These materials are not a solicitation of a proxy from any security holder of the Company. Daniel J. Mangless has nominated Travis C. Mickle, PhD and Arthur C. Regan as nominees to the Company’s board of directors (the “Nominees”) and intends to solicit votes for the election of the Nominees as members of the Company’s board of directors. Mr. Mangless will send a definitive proxy statement, BLUE proxy card and related proxy materials to shareholders of the Company seeking their support of the Nominees at the Company’s 2025 annual meeting of stockholders. Stockholders are urged to read the definitive proxy statement and BLUE proxy card when they become available, because they will contain important information about the Nominees, the Company and related matters. Shareholders may obtain a free copy of the definitive proxy statement and BLUE proxy card (when available) and other documents filed by Mr. Mangless with the Securities and Exchange Commission (“SEC”) at the SEC’s web site at www.sec.gov. Shareholders may also direct a request to Mr. Mangless’ proxy solicitor, Regan & Associates, Inc., 505 Eighth Avenue, Suite 800, New York, NY 10018 (shareholders can e-mail at main@reganproxy.com or call toll-free at (800) 737-3426).

Participants in Solicitation

Daniel J. Mangless together with Travis C. Mickle, PhD and Arthur C. Regan (the “Mangless Group”) are the participants in the solicitation by Mr. Mangless. The participants may have interests in the solicitation, including as a result of holding shares of the Company’s common stock. Mr. Mangless filed an amended preliminary proxy statement under cover of Schedule 14A on April 16, 2025 (the “Preliminary Proxy Statement”). Information regarding the participants and their interests is contained in the Preliminary Proxy Statement.